Xilio Therapeutics, Inc. Common Stock

XLO US98422T1007

💰
Capitalization
Small-cap

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies (including bispecifics) and immune cell engagers (including tumor-activated cell engagers and tumor-activated effector-enhanced cell engagers).

🔗
Website
https://www.xiliotx.com
Annual Performance 1
2021 2022 2023 2024 2025
0% -83% -80% 67% 0%
Annual Insiders Turnover, USD 2

1 annual and historical performance metrics are recalculated on a daily basis;
2 represents the total value of insider transactions (both buying and selling);

Insider Activity
📊
Transactions
7
🙍
Insiders
5
Person Price Shares Total Published Completed
Shannon James Samuel
O 		0.69
USD 		25,000
Bought 		17,215
USD 		16/06/2025 17/06/2025
Shannon James Samuel
O 		0.69
USD 		45,000
Bought 		30,870
USD 		16/06/2025 16/06/2025
Russo Rene
CEO 		0.68
USD 		36,289
Bought 		24,680
USD 		16/06/2025 16/06/2025
Brennan Kevin M.
CCO 		0.98
USD 		1,803
Sold 		1,774
USD 		01/01/2025 02/01/2025
Frankenfield Christopher James
CFO 		0.98
USD 		6,954
Sold 		6,841
USD 		01/01/2025 02/01/2025
Gilead Sciences, Inc.
 1.04
USD 		1,759,978
Bought 		1,830,377
USD 		18/12/2024 18/12/2024
Gilead Sciences, Inc.
 0.76
USD 		485,250
Bought 		368,790
USD 		02/04/2024 02/04/2024
Integrated EOD Stock Data and Insider Transactions Chart

Sign in or subscribe to include Xilio Therapeutics, Inc. Common Stock to your watchlist and receive automatic alerts for upcoming transactions.

The visibility of insider buy and sell transactions on this chart should not be the sole factor in your decision to buy or sell a particular stock. Always consider the following dynamic reports for a broader understanding of stock market activities:

 

Historical Performance
1M 3M 6M 1Y 3Y 5Y All Time
22% -1% 38% -68% 0% 0% -94%
Last 52W Low 52W High All-Time Low All-Time High β
0.82 0.65 1.48 0.50 25.11
Company Insiders
Person / Entity Transactions Turnover, USD Average, USD First Last
Gilead Sciences, Inc. 2 2,199,167.12 1,099,583.56 02/04/2024 18/12/2024
Shannon James Samuel 2 48,085.00 24,042.50 16/06/2025 17/06/2025
Russo Rene 1 24,680.15 24,680.15 16/06/2025 16/06/2025
Frankenfield Christopher James 1 6,840.65 6,840.65 02/01/2025 02/01/2025
Brennan Kevin M. 1 1,773.61 1,773.61 02/01/2025 02/01/2025

Insiders marked in yellow represent long-term insiders. These are individuals who have engaged in transactions for over 3 years and have conducted at least 10 transactions or reached a cumulative turnover of $1M USD. When examining transaction clusters, we prioritize those conducted by long-term insiders for analysis.

Stock Advanced Metrics
Delta Correlation subscribe 🔒
Upper Bound of Standardized Transaction Amount (ubsta), USD 4 subscribe 🔒

4 represents the maximum expected transaction amount for a company's insiders, calculated based on historical data. It provides insight into the typical range of insider transaction amounts and helps in identifying unusually large transactions.

5 a proprietary metric reflecting the consistency of insider trading behavior within a company. A higher discipline index suggests more regular and predictable insider transactions.